SCHEMBL24680922

SCHEMBL24680922

COc1cc(C(C)C)ccc1C=N

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
ERN1 O75460 1/20 0.41
TYR P14679 1/20 0.41
CYP1A1 P04798 6/20 0.40
CYP1A2 P05177 6/20 0.40
CYP1B1 Q16678 6/20 0.40
NFE2L2 Q16236 3/20 0.40
ALDH1A1 P00352 4/20 0.38
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
FGFR2 P21802 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2467985 0.85 HDAC4 (0.43) HDAC4HDAC8ERN1TYRCYP1A1
SCHEMBL2290188 0.81 ALDH1A1 (0.59) HDAC4HDAC8ERN1TYRCYP1A1
SCHEMBL13557887 0.78 TYR (0.47) HDAC4HDAC8TYRALDH1A1MAPT
SCHEMBL84033 0.76 PPARG (0.53) HDAC4HDAC8CYP1A2ALDH1A1MAPT
SCHEMBL3785302 0.75 CYP1A2 (0.70) CYP1A1CYP1A2CYP1B1NFE2L2ALDH1A1
SCHEMBL21167752 0.75 TYR (0.44) TYRALDH1A1MAPTL3MBTL1POLB
SCHEMBL24240700 0.75 LMNA (0.47) TYRALDH1A1MAPTMAPK1L3MBTL1
SCHEMBL4199940 0.74 HDAC4 (0.43) HDAC4HDAC8ERN1TYRCYP1A1
SCHEMBL7448262 0.74 TYR (0.53) HDAC4HDAC8ERN1TYRNFE2L2
SCHEMBL12870076 0.74 KDM4E (0.57) NFE2L2ALDH1A1MAPTMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022235575-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION (US) 2022-11-10 WO disclosed